Abstract
New regimens consisting of pegylated interferons plus ribavirin may produce a sustained virologic response in more than 50% of cases of chronic hepatitis C. In contrast, the combination of standard interferon alfa and ribavirin, which was the standard of care until recently, produced a sustained virologic response in 35% to 40% of cases. As the efficacy of newer regimens improves, additional steps to adequately manage their side effects and maximize adherence may become crucial.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antiviral Agents / therapeutic use*
-
Drug Therapy, Combination
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use*
-
Polyethylene Glycols / therapeutic use*
-
Recombinant Proteins
-
Ribavirin / therapeutic use
-
Treatment Outcome
Substances
-
Antiviral Agents
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2b
-
peginterferon alfa-2a